Voclosporin
A semisynthetic cyclosporine analog and oral calcineurin inhibitor, approved by the FDA on January 22, 2021 as Lupkynis for adults with active lupus nephritis in combination with background immunosuppressive therapy, the first oral drug approved for that indication.
Also referenced as: ISA247, ISATX247, E-ISA247, LX211, LX214, Lupkynis, QLG1074
Public product evidence No certificate records are bound to a tracked Voclosporin product page A record counts here only when a vendor publishes a certificate against one of its own tracked Voclosporin product pages. Other certificates naming this compound may still exist — search the wider certificate database.This compound maps to at least one regulated medical product or label context in the United States.
This profile is grouped by its dominant research area, not by vendor shelf placement.
Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.
ISA247, ISATX247, E-ISA247, LX211, LX214, Lupkynis, QLG1074
FDA label signal · 29 trials · 216 PubMed results
Voclosporin is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.
Voclosporin has 18 name-matched clinical trials (highest phase: Phase 4) and 216 PubMed-indexed publications and holds an FDA drug label. 7 trials have posted results.
Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Voclosporin?
Voclosporin is a semisynthetic analog of cyclosporine, the fungal cyclic undecapeptide that has anchored transplant immunosuppression since the 1980s. Like its parent it is a non-ribosomal cyclic peptide: a ring of 11 amino acids, several N-methylated and one non-proteinogenic, assembled by a non-ribosomal peptide synthetase rather than translated from mRNA, and here further modified chemically. The single change sits at amino acid 1, the unusual residue whose side chain projects out of the ring toward calcineurin; voclosporin carries an extended side chain there, and the marketed drug is the E (trans) geometric isomer, originally designated E-ISA247, which binds cyclophilin A with an affinity of 15 nM against 61 nM for the Z isomer (Kuglstatter et al., Acta Crystallographica Section D, 2011;67(Pt 2):119–123). The US label gives a molecular weight of 1214.6 g/mol and describes a white to off-white solid, practically insoluble in water.
The molecule was invented at Isotechnika in Edmonton, Alberta as ISA(TX)247, developed for psoriasis, kidney transplantation and uveitis without reaching the market in any of them, and approved by the FDA on January 22, 2021 as Lupkynis, the first oral therapy approved in the US specifically for lupus nephritis. It is available only as a prescription product.
How it works
- Cyclophilin-mediated calcineurin inhibition. Voclosporin binds cyclophilin A inside lymphocytes; the complex blocks calcineurin’s phosphatase activity, so the transcription factor NFAT stays phosphorylated in the cytoplasm and T-cell cytokine genes are not switched on. The co-crystal structure shows the modified side chain of the E isomer making superior van der Waals contacts with cyclophilin A and suggests it induces structural changes in calcineurin that explain voclosporin’s greater potency relative to cyclosporine (Kuglstatter et al., Acta Crystallographica Section D, 2011;67(Pt 2):119–123). The label states that the full mechanism has not been established but describes reduced lymphocyte proliferation, T-cell cytokine production and T-cell activation-antigen expression.
- A tight concentration–effect relationship. In healthy volunteers given single oral doses from 0.25 to 4.5 mg/kg, exposure rose linearly, calcineurin inhibition tracked blood concentration with an EC50 of 78.3 ng/mL, and a high-fat meal cut peak concentration by 53% and total exposure by 25% (Mayo et al., Journal of Clinical Pharmacology, 2013;53(8):819–826). The label reports a peak about 1.5 hours after a fasting dose, a terminal half-life of roughly 30 hours and little lag between peak concentration and peak calcineurin inhibition, the basis for fixed dosing without the blood-level monitoring cyclosporine and tacrolimus require.
- CYP3A4 and transporter interactions. Voclosporin is a sensitive CYP3A4 substrate: ketoconazole raised its exposure 18-fold and verapamil 2.7-fold, rifampin reduced it, and voclosporin raised digoxin exposure through P-glycoprotein inhibition (Ling et al., British Journal of Clinical Pharmacology, 2014;77(6):1039–1050).
- Direct effects on T cells and podocytes. Voclosporin suppressed experimental autoimmune uveoretinitis in rats and inhibited human T-cell proliferation in vitro by up to 100-fold (Cunningham et al., Investigative Ophthalmology & Visual Science, 2009;50(1):249–255). The label also cites animal data for a non-immunological stabilization of the podocyte actin cytoskeleton, a plausible contributor to the rapid fall in proteinuria seen in lupus nephritis trials.
Research status
Origins and psoriasis. ISA(TX)247 was presented as a novel calcineurin inhibitor in 2001 (Aspeslet et al., Transplantation Proceedings, 2001;33(1–2):1048–1051). A 12-week phase 2 trial in 201 psoriasis patients produced PASI 75 responses in 0% on placebo, 18.2% at 0.5 mg/kg/day and 66.7% at 1.5 mg/kg/day (Bissonnette et al., Journal of the American Academy of Dermatology, 2006;54(3):472–478). The phase 3 trial (NCT00244842) randomized 451 patients to placebo or ISA247 0.2, 0.3 or 0.4 mg/kg twice daily; PASI 75 at week 12 was reached by 16%, 25% and 47% of the active groups versus 4% on placebo, with mild to moderate glomerular filtration rate reductions in seven patients at the top dose and one at the middle dose (Papp et al., Lancet, 2008;371(9621):1337–1342). A second phase 3 trial against placebo and ciclosporin (NCT00408187, 642 patients) completed in December 2008 without an indexed publication, and no psoriasis approval followed.
Kidney transplantation. PROMISE (NCT00270634), a 6-month open-label phase 2b trial in 334 kidney transplant recipients, compared three voclosporin exposure levels with tacrolimus. Biopsy-proven acute rejection occurred in 10.7%, 9.1% and 2.3% of the voclosporin groups versus 5.8% on tacrolimus, meeting noninferiority, and new-onset diabetes after transplantation was 1.6%, 5.7% and 17.7% versus 16.4% (Busque et al., American Journal of Transplantation, 2011;11(12):2675–2684). A phase 3 transplant trial (NCT01586845) was withdrawn before enrolling anyone.
Uveitis and dry eye. Lux Biosciences developed the molecule as LX211 and ran the LUMINATE phase 3 program in noninfectious uveitis (Anglade et al., Clinical Ophthalmology, 2008;2(4):693–702). The last trial, 155 patients with active uveitis (NCT01243983), completed in December 2012 with no results posted and no primary publication indexed. A topical formulation (LX214, later VOS) was tested at 0.05%, 0.1% and 0.2% against vehicle in the 508-patient AUDREY trial (NCT04147650); it missed its primary endpoint of a 10 mm or greater Schirmer tear test improvement at week 4; the trial completed on October 8, 2020 and no further ophthalmic study was registered. A phase 2 study in focal segmental glomerulosclerosis (NCT03598036) was terminated for low recruitment after five participants.
AURA-LV (NCT02141672). The phase 2 lupus nephritis trial randomized 265 patients at 79 centers in 20 countries to voclosporin 23.7 mg or 39.5 mg twice daily or placebo, all on mycophenolate mofetil and rapidly tapered low-dose corticosteroids. Complete renal remission at 24 weeks was 32.6% with the low dose, 27.3% with the high dose and 19.3% with placebo (odds ratio 2.03 for low dose versus placebo). Serious adverse events were more frequent in both voclosporin groups and deaths were concentrated in the low-dose arm (11.2% versus 1.1% on placebo and 2.3% on high dose) (Rovin et al., Kidney International, 2019;95(1):219–231).
AURORA 1 (NCT03021499). The pivotal phase 3 trial enrolled 357 patients with biopsy-proven class III, IV or V lupus nephritis at 142 sites in 27 countries, randomized 1:1 to voclosporin 23.7 mg twice daily or placebo on top of mycophenolate mofetil and a rapid steroid taper. Complete renal response at week 52, a composite of urine protein-creatinine ratio of 0.5 mg/mg or less, stable kidney function, no rescue medication and low-dose steroids, was achieved by 41% on voclosporin versus 23% on placebo (odds ratio 2.65; 95% CI 1.64–4.27; p<0.0001). Serious adverse events occurred in 21% of each group, and one patient on voclosporin and five on placebo died, none judged treatment-related (Rovin et al., Lancet, 2021;397(10289):2070–2080). The death imbalance seen in AURA-LV did not recur.
AURORA 2 (NCT03597464). 216 AURORA 1 completers continued their blinded assignment for two more years; 86.1% finished. Glomerular filtration rate decrease (10.3% versus 5.0%) and hypertension (8.6% versus 7.0%) were more common on voclosporin, yet the two-year eGFR slope was −0.2 mL/min/1.73 m² on voclosporin against −5.4 on control, and complete renal response at three years favored voclosporin (50.9% versus 39.0%; odds ratio 1.74; 95% CI 1.00–3.03) (Saxena et al., Arthritis & Rheumatology, 2024;76(1):59–67). In 16 voclosporin-treated and 10 control patients with repeat biopsies after about 18 months, histopathology showed no sign of calcineurin-inhibitor nephrotoxicity (Rovin et al., Arthritis & Rheumatology, 2025;77(10):1387–1393). A 2026 meta-analysis of the two randomized trials estimated a relative risk of complete renal response of 1.78 (95% CI 1.35–2.34) and concluded that trial designs preclude any reliable indirect comparison with tacrolimus regimens (Zala et al., Journal of Clinical Medicine, 2026;15(19):7607).
Regulatory path. NDA 213716 was approved on January 22, 2021 for adults with active lupus nephritis in combination with a background immunosuppressive regimen; an efficacy supplement with clinical data was approved on April 29, 2024, and the current label is dated October 2025. The European Commission issued a marketing authorization on September 15, 2022, with Otsuka Pharmaceutical Netherlands B.V. as holder (ATC code L04AD03); the Great Britain authorization dates from November 29, 2022, Swissmedic granted its first authorization on April 24, 2023, and Japan approved Lupkynis Capsules 7.9 mg (Otsuka Pharmaceutical) for lupus nephritis on September 24, 2024. In China, Qilu Pharmaceutical is running a 270-patient phase 3 trial of its voclosporin product QLG1074 (NCT06406205), with primary completion estimated for June 2027.
Pediatric program and ongoing work. VOCAL (NCT05288855), a placebo-controlled phase 3 study in adolescents and children with lupus nephritis, began on October 10, 2023 and was terminated on July 3, 2025 after enrolling nine participants, with the registry citing a data safety monitoring board recommendation; its open-label extension (NCT05962788) ended the next day with four participants. In adults, PRESERVE (NCT07611214), a 150-patient phase 4 trial of Lupkynis combined with belimumab, obinutuzumab or anifrolumab, started on April 22, 2026 with primary completion estimated for March 2, 2029.
Common dosage forms
- Lupkynis capsules. 7.9 mg voclosporin soft gelatin capsules for oral use, dispensed by prescription and taken by the patient.
- Investigational oral capsules. ISA247 capsules used in the psoriasis and transplant trials, supplied only to study sites and never marketed.
- Ophthalmic solution. Voclosporin ophthalmic solution at 0.05%, 0.1% and 0.2% (LX214, VOS) was used only in uveitis and dry-eye trials and was never approved or marketed.
Key considerations
- Regulatory status. The FDA Approved status reflects the January 22, 2021 approval of Lupkynis (voclosporin) capsules under NDA 213716 for adults with active lupus nephritis in combination with a background immunosuppressive regimen. The product is also authorized in the European Union, Great Britain, Switzerland and Japan, the US label covers adults only, and the pediatric trials were terminated in 2025.
- A cyclosporine with a changed side chain, not a new class. The modification at amino acid 1 raises potency and gives a predictable exposure–response relationship that allowed fixed dosing without blood-level monitoring, but the pharmacology remains that of a calcineurin inhibitor, and the US label carries the class boxed warning for malignancies and serious infections.
- Kidney function is the central trade-off. Falls in eGFR were the most frequently reported adverse reaction in the pivotal trials, yet the three-year eGFR slope in AURORA 2 was flatter on voclosporin than on control and repeat biopsies showed no histologic sign of nephrotoxicity. Controlled follow-up in the published trials ends at three years.
- Interaction constraints. As a sensitive CYP3A4 substrate whose exposure rose 18-fold under ketoconazole, voclosporin cannot be combined freely with CYP3A4 inhibitors or inducers, and its fixed-dose regimen depends on avoiding them rather than on blood-level monitoring.
- Naming. ISA247, ISATX247, E-ISA247, LX211, LX214, QLG1074 and Lupkynis all refer to voclosporin; the E isomer is the active drug and the Z isomer a less potent stereoisomer, not a separate product. Evidence for one calcineurin inhibitor in lupus nephritis does not transfer to another.